Bhuvan Chugh, Lead Consultant at Apollo Hospitals, shared on LinkedIn:
“Invasive lobular breast cancer is not just ductal cancer with a different shape.
Its biology is different. ER-Axis is different. Tamoxifen is likely a less optimal endocrine strategy in ILC.”
